hallucination

Scales to assess psychosis in Parkinson’s disease: Critique and recommendations

By Hubert H. Fernandez MD, Dag Aarsland MD, Gilles Fénelon MD, Joseph H. Friedman MD, Laura Marsh MD, Alexander I. Tröster PhD, Werner Poewe MD, Olivier Rascol MD, Cristina Sampaio MD, Glenn T. Stebbins PhD and Christopher G. Goetz MD

Psychotic symptoms are a frequent occurrence in Parkinson’s disease (PD), affecting up to 50% of patients. The Movement Disorder Society established a Task Force on Rating Scales in PD, and this critique applies to published, peer-reviewed rating psychosis scales used in PD psychosis studies. Twelve psychosis scales/questionnaires were reviewed. None of the reviewed scales adequately…

Severity of neuropsychiatric symptoms and dopamine transporter levels in dementia with Lewy bodies: A 123I-FP-CIT SPECT study

By Francesco Roselli MD, Nicola M. Pisciotta MD, Robert Perneczky MD, Michele Pennelli MSc(Psych), Maria S. Aniello MD, Maria F. De Caro PhD, Ermanno Ferrannini MD, Bruno Tartaglione MD, Giovanni Defazio MD, PhD, Giuseppe Rubini MD and Paolo Livrea MD, PhD

Neuropsychiatric symptoms are frequent in dementia with Lewy bodies (DLB). Dopamine transporter (DAT) imaging with 123I-labeled ligand N-δ-(fluoropropyl)-2β-carbomethoxy-3β-(4-iodophenyl)tropene (123I-FP-CIT), which reliably measures midbrain dopaminergic dysfunction, has provided important evidence on the neurobiological substrate of some of these symptoms including apathy and depression. However, little is known on DAT levels and other distressing symptoms such as…

hallucination

Footer